Combination of GLP-1 receptor agonists and SGLT2 inhibitors in cardiometabolic disease: synergistic, additive, or non-additive effects? A narrative review
Combining two diabetes drugs produces additive benefits in weight, blood sugar, and blood pressure, though larger studies are needed to confirm superiority.
This narrative review synthesizes RCT and real-world evidence on the GLP-1RA + SGLT2 inhibitor combination, confirming additive glycemic, weight, and blood pressure effects across multiple trials while noting insufficient RCT data to confirm synergistic cardiovascular or renal superiority beyond individual agents. The review contextualizes clinical practice guidance with the caveat that combination-specific outcome trials are still needed.
What the study was
- Study design
- Narrative review of RCTs, observational studies, post-hoc analyses, and meta-analyses
- Population
- Adults with T2DM and high cardiovascular risk; non-diabetic populations with obesity or HFpEF
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Cardiovascular Diabetology
Why it surfaced
Clinically useful synthesis for cardiometabolic practice. Narrative review format limits score. Published in Cardiovascular Diabetology (focused journal). Timely given growing use of combination regimens in clinical practice.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.